[1]孙媛 田秀秀 ? 丁江生.三七不同药用部位中人参皂苷Rg3的含量测定[J].现代中医药,2021,(02):029-34.[doi:10.13424/j.cnki.mtct.2021.02.006]
　SUN Yuan,TIAN Xiu - xiu,DING Jiang - sheng.Determination of Ginsenoside Rg3 in Different Parts of Panax Notoginseng[J].Modern Traditional Chinese Medicine,2021,(02):029-34.[doi:10.13424/j.cnki.mtct.2021.02.006]
点击复制

三七不同药用部位中人参皂苷Rg3的含量测定()
分享到：

《现代中医药》[ISSN:1006-6977/CN:61-1281/TN]

卷:
期数:
2021年02期
页码:
029-34
栏目:
出版日期:
2023-11-20

文章信息/Info

Title:
Determination of Ginsenoside Rg3 in Different Parts of Panax Notoginseng
文章编号:
1672-0571(2021)02-0029-06
作者:
孙媛 1; 2; 3田秀秀 1; 2; 3? 丁江生 1; 2; 3
1.云南省药物研究所,云南昆明650111;
2.云南白药集团创新研发中心,云南昆明650111;
3.云南省中药和民族药新药创制企业重点实验室,云南昆明650111
Author(s):
SUN Yuan 1; 2; 3 ;  TIAN Xiu - xiu 1; 2; 3 ;  DING Jiang - sheng 1; 2; 3
1. Yunnan pharmaceutical research institute, Kunming 650111, China;
2. Innovation and R & D center of Yunnan Baiyao group, Kunming 650111, China;
3. Key laboratory of new drug creation enterprises of traditional Chinese medicine and ethnic medicine in Yunnan province, Kunming 650111, China
关键词:
三七; 含量测定; 20(S)-人参皂苷Rg3; 20(R)-人参皂苷Rg3
Keywords:
Panax notoginseng;  Content determination;  20 (S) - Ginsenoside Rg3;  20 (R) - Ginsenoside Rg3
分类号:
R282.6
DOI:
10.13424/j.cnki.mtct.2021.02.006
文献标志码:
A
摘要:
目的建立三七中20(S)-人参皂苷Rg3和20(R)-人参皂苷Rg3的含量测定方法,评价不同药用部位及加工方式的三七提取物中,两个型的人参皂苷Rg3的含量情况?方法采用高效液相色谱法测定,色谱条件:ECOSIL120-5-C18-SH色谱柱(4.6×250mm,5μm);流动相为乙腈-异丙醇-水(47:3:50);流速:1.0ml·min-1;检测波长:203nm;进样量:10μL;柱温:20℃;测定不同药用部位及加工方式的三七提取物中20(S)-人参皂苷Rg3和20(R)-人参皂苷Rg3的含量?结果20(S)-人参皂苷Rg3的含量测定线性范围14.0~279.6μg·ml-1,(r2=1.0000),平均加样回收率100.56%,RSD2.46%?20(R)-人参皂苷Rg3的含量测定线性范围14.1~282.0μg·ml-1,(R2=0.9999),平均加样回收率101.51%,RSD2.99%?结论该测定方法简便?稳定?高效;三七不同药用部位中根材优于其他药用部位;熟三七中20(S)-人参皂苷Rg3含量明显升高?
Abstract:
Objective To establish a method for the determination of 20 ( s) - Ginsenoside Rg3 and 20 ( R) - Ginsenoside Rg3 in Panax notoginseng, and to evaluate the content of two types of Ginsenoside Rg3 in Panax notoginseng extracts from different medicinal parts and processing methods. Methods HPLC was used to determine the content. The chromatographic conditions were as follows: ecosil 120 -5 - c18 - sh column ( 4. 6 × 250mm, 5μm) ; The mobile phase was acetonitrile - isopropanol - water ( 47: 3: 50) ; the flow rate was 1. 0ml· min -1 ; the detection wavelength was 203nm; the injection volume was 10 μ L; the column temperature was 20 ℃; the contents of 20 ( s) - Ginsenoside Rg3 and 20 ( R) - Ginsenoside Rg3 in different medicinal parts and processing methods of Panax notoginseng extract were determined. Results the linear range of 20 ( s) - Ginsenoside Rg3 was 14. 0 ~ 279. 6 μ g · ml-1 ( r 2= 1. 0000) .The average recovery was 100. 56%, RSD 2. 46%. The linear range of 20 ( R) - Ginsenoside Rg3 was 14. 1 ~ 282. 0μ g · ml-1 ( R 2= 0. 9999) . The average recovery was 101. 51%, RSD 2. 99%. Conclusion The content of 20 ( s) -Ginsenoside Rg3 in cooked Panax notoginseng increased significantly.

参考文献/References:

[1]国家药典委员会,中华人民共和国药典:一部[M].北京:中国医药科技出版社,2020.
[2]乔春玲,丁艳芬,杨崇仁.三七总皂苷药理研究进展[J].中国现代中药,2012,14(11):25-30.
[3]于善娟.HPLC法测定红参浸膏中人参皂苷Rg1?Re?Rb1和Rg3的含量[J].现代食品,2019,(10):181-186.
[4]翁砚,王晓非,刘同帅,等.HPLC法测定人参皂苷Rg3?Rh1的含量[J].长春中医药大学学报,2016,32(2):256-258.
[5] Zhang Fei , Li Mao - Lan , Wu Xiangsong , et al. 20( S)- ginsenoside Rg3 promotes senescence and apoptosis in gallbladder cancer cells via the p53 pathway. [J]. Drug design , development and therapy, 2015, 9:3969 -3987.
[6] Qiu Xiao - Min , Bai Xue , Jiang Hong - Fang , et al. 20 - ( s) - ginsenoside Rg3 induces apoptotic cell death in human leukemic U937 and HL - 60 cells through PI3K/Akt pathways. [J]. Anti - cancer drugs , 2014 , 59:1072 -1080.
[7] Wang Jia - He , Nao Jian - Fei , Zhang Meng , et al 20( s) - ginsenoside Rg3 promotes apoptosis in human ovarian cancer HO - 8910 cells through PI3K/ Akt and XIAP pathways. [J]. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine , 2014 , 3512:11985 -11994.
[8] Yuan Hai - Dan , Quan Hai - Yan , Zhang Ya , et al. 20 (S) - Ginsenoside Rg3 - induced apoptosis in HT – 29 colon cancer cells is associated with AMPK signaling pathway. [J]. Molecular medicine reports , 2010 , 35:825 -831.
[9] Kim Dong - Gun , Jung Kyung Hee , Lee Da - Gyum , et al. 20( S) - Ginsenoside Rg3 is a novel inhibitor of autophagy and sensitizes hepatocellular carcinoma to doxorubicin. [J]. Oncotarget , 2014 , 512: 4438 -4451.
[10] Yu TY. Impact analysis of clinical effect of chemotherapy and immunologic function on advanced NSCLC with shenyi capsule. [J]. Chin J of Immun ( 中 国 免 疫 学 杂 志 ) ,2018 , 34:1012 -1016.
[11]高培新,刘勇,侯德志.浅谈人参皂苷Rg3和Rh2抗癌研究成果[J].当代医学,2019,25(26):193-194.
[12]吉丽娜,冯伟红,王智民,等.HPLC-DAD测定人参首乌胶囊中8种人参皂苷类成分[J].中国中药杂志,2013,38(17):2798-2802.
[13]蒋钰为,孙涛.人参皂苷Rg3对人乳腺癌细胞株MCF-7增殖及凋亡的影响[J].中医临床研究,2020,(14):1-4.
[14]扈婷婷,蔡宏懿.人参皂苷Rg3对大鼠急性放射性直肠炎的实验研究[J].中华放射肿瘤学杂志,2019,(11):854-857.
[15]赵永军,李刚刚,孙治安.人参皂苷Rg3对肝细胞癌上皮间质转化的抑制作用机制研究[J].中国临床药理学杂志,2020,(14):2066-2069.
[16]熊暮臖,黄靓.人参皂苷Rg3对急性髓细胞性白血病THP-1?HL-60细胞的干预作用[J].中医学报,2020,(7):1497-1500.
[17]杨玉,陈春林.人参皂苷Rg3的药理作用研究现状[J].中国临床药理学杂志,2019,(5):497-500.
[18]缪志伟,严晶,顾鸣佳,等.人参皂苷Rg3对DSS诱导的溃疡性结肠炎小鼠Th1/Th2失衡的影响[J].中药药理与临床,2019,(1):47-51.
[19]赵灵琴,寿华锋,陈鲁,等.人参皂苷Rg3对卵巢癌原代细胞增殖?迁移及凋亡的影响[J].浙江中医杂志,2019,(9):662-663.
[20]黄捷,吴可人,徐涛,等.人参皂苷Rg3通过内质网应激PERK通路抑制人胆囊癌裸鼠移植瘤生长的研究[J].浙江医学,2018,(22):2415-2418.

相似文献/References:

[1]张 莹.超高效液相色谱法同时测定维 Ｃ银翘片中的多种成分的含量[J].现代中医药,2019,(05):103.[doi:10.13424/j.cnki.mtcm.2019.05.031]
[2]甄亚钦１,２,３ 田伟１,等.ＨＰＬＣ 同时测定肉苁蓉配方颗粒中 ４ 种成分的含量[J].现代中医药,2019,(01):083.[doi:10.13424/j.cnki.mtcm.2019.01.029]
[3]杨文文１ 党珍２ 王西芳１.陕西产香青兰重金属元素含量的分析测定[J].现代中医药,2019,(01):092.[doi:10.13424/j.cnki.mtcm.2019.01.031]
[4]锡林通嘎拉嘎 水兰 包勒朝鲁.蒙药三红汤中大叶茜草素的含量测定[J].现代中医药,2021,(02):035.[doi:10.13424/j.cnki.mtct.2021.02.007]
　XILIN Tong-ga-la-ga,SHUI Lan,BAOLE Chao-lu.Determination of Rubicin in Mongolian Medicine Sanhong Decoction[J].Modern Traditional Chinese Medicine,2021,(02):035.[doi:10.13424/j.cnki.mtct.2021.02.007]
[5]杨宗辉.HPLC-ELSD测定酸枣仁元知软胶囊中酸枣仁皂苷A的含量[J].现代中医药,2021,(02):040.[doi:10.13424/j.cnki.mtct.2021.02.008]
[6]倪志涛 杜晓凤 史玉攀 商婷 王谨慧.大黄消痔栓的工艺改进及有效成分含量测定[J].现代中医药,2021,(03):034.[doi:10.13424/j.cnki.mtcm.2021.03.008]
　NIZhitao,DUXiaofengSHIYupan,SHANGTing,et al.TechnologicalImprovementofDahuangXiaozhiSuppositoryandDeterminationofItsActiveComponents[J].Modern Traditional Chinese Medicine,2021,(02):034.[doi:10.13424/j.cnki.mtcm.2021.03.008]
[7]王发英 吴查青 陈张金 刘敏 余华丽 王伟影.市售麝香壮骨膏的质量评价[J].现代中医药,2021,(05):041.[doi:0.13424/j.cnki.mtcm.2021.05.007]
[8]赵颖林 冯小燕 王显著 马强 贺麟桀 王卫锋.医院制剂滑膜膏质量标准的提升研究[J].现代中医药,2022,1(05):052.[doi:10.13424/j.cnki.mtcm.2022.05.009]
[9]姬莎莎 刘红波 朱华旭 宋忠兴 李国龙 杨海燕.北柴胡标准汤剂的制备与质量评价研究*[J].现代中医药,2023,(02):102.[doi:10.13424/j.cnki.mtcm.2023.02.021]
[10]卢立炜 陈睿 梁天坚 刘亿雨 黎凤仪.基于CiteSpace近30年中医药治疗 酒精性肝病可视化分析[J].现代中医药,2023,(03):006.[doi:10.13424/j.cnki.mtcm.2023.03.002 ]

备注/Memo

备注/Memo:
基金项目:云南省科技厅“重大科技专项(生物医药)”(2018ZF013)
作者简介:孙媛,高级工程师?E-mail:stary1982@163.com
更新日期/Last Update: 2021-03-26